
Sign up to save your podcasts
Or


In the first episode of a special daily series during the 2026 ASCO Annual Meeting, Dr. Monty Pal discusses 3 abstracts, including a follow-up on the EV-302 study in urothelial carcinoma, a potential new treatment option for patients with PD-L1-positive advanced non–small cell lung cancer, and a novel psychosocial digital application that improves fatigue and distress in patients with multiple myeloma.
LINK TO FULL TRANSCRIPT
By American Society of Clinical Oncology (ASCO)4.6
5656 ratings
In the first episode of a special daily series during the 2026 ASCO Annual Meeting, Dr. Monty Pal discusses 3 abstracts, including a follow-up on the EV-302 study in urothelial carcinoma, a potential new treatment option for patients with PD-L1-positive advanced non–small cell lung cancer, and a novel psychosocial digital application that improves fatigue and distress in patients with multiple myeloma.
LINK TO FULL TRANSCRIPT

319 Listeners

506 Listeners

40 Listeners

65 Listeners

766 Listeners

122 Listeners

2,237 Listeners

821 Listeners

188 Listeners

47 Listeners

31 Listeners

837 Listeners

59 Listeners

195 Listeners

46 Listeners